Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2L9MD
|
|||
| Drug Name |
RG6524
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Co-stimulatory molecule 4-1BB (CD137) | Target Info | . | [1] |
| Delta-like protein 3 (DLL3) | Target Info | . | [1] | |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [1] | |
| KEGG Pathway | Endocrine resistance | |||
| Notch signaling pathway | ||||
| Th1 and Th2 cell differentiation | ||||
| Pathways in cancer | ||||
| Breast cancer | ||||
| Cytokine-cytokine receptor interaction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Roche | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.